Document is current
Any future updates will be listed below
-
Authors
Haddad, T. S.
Bokhorst, J. M.
Berger, M. D.
Dobbelsteen, L. v. d.
Simmer, F.
Ciompi, F.
Galon, J.
Laak, J. v. d.
Pagès, F.
Zlobec, I.
Lugli, A.
Nagtegaal, I. D.
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (10602/2016-2)
- License Information
-
More Information
Article History
Received: 18 July 2024
Accepted: 31 October 2024
First Online: 2 December 2024
Declarations
:
: JG and FP have patents associated with the immune prognostic biomarkers. JG is co-founder of HalioDx, a Veracyte company, and part-time employee of Veracyte. Immunoscore® a registered trademark owned by the National Institute of Health and Medical Research (INSERM) and licensed to Veracyte. JvdL was a member of the advisory boards of Philips, the Netherlands and ContextVision, Sweden, and received research funding from Philips, the Netherlands, ContextVision, Sweden, and Sectra, Sweden in the last five years. He is chief scientific officer (CSO) and shareholder of Aiosyn BV, the Netherlands. FC was Chair of the Scientific and Medical Advisory Board of TRIBVN Healthcare, France, and received advisory board fees from TRIBVN Healthcare, France in the last five years. He is shareholder of Aiosyn BV, the Netherlands. All other authors declare no conflict of interest.
